# Eli Lilly and Company: Phase 1 study terminated, 77 enrolled (Overweight or Obesity, Healthy)

**Score:** 45/100

| Field | Value |
|---|---|
| Sponsor | Eli Lilly and Company |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | A Study of LY4064912 in Healthy Participants and With Overweight or Obesity |
| NCT ID | NCT07152002 |
| Phase | Phase 1 |
| Status | terminated |
| Conditions | Overweight or Obesity; Healthy |
| Intervention types | drug |
| Target enrollment | 77 |
| Site countries | United States, Singapore |
| Posted | 2025-09-03 |
| Planned start | 2025-08-28 |
| Event | Terminated |
| Event date | 2026-08-26 |
| Last update posted | 2026-09-14 |

## Why this score
- Industry sponsor (buys outsourced services).
- Stopped early: budget and sites freed up.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07152002). Last refreshed: 2026-11-05T08:46:16.625Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.